| Citation: |
WANG Lu, LI Xiaolu, XU Xiaofan, GU Jun, YU Zhenghong. Action mechanism of seaweed-kunbu in treatment of breast cancer based on network pharmacology[J]. Journal of Clinical Medicine in Practice, 2024, 28(16): 19-25. DOI: 10.7619/jcmp.20233370
|
To analyze the mechanism of action of seaweed-kunbu in the treatment of breast cancer through network pharmacology.
The active ingredients and their targets of seaweed-kunbu were retrieved through the TCMSP database. Relevant targets for breast cancer were obtained through the GeneCards and OMIM databases, and "drug-disease target" network diagram was constructed using Cytoscape software. Protein-protein interaction (PPI) network analysis was performed using the String platform. Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using R language. Molecular docking technology was used to verify the binding ability of key compounds to targets, and functional verification was carried out through in vitro experiments.
A total of 11 effective compounds were obtained from seaweed-kunbu in this study, among which 10 were related to breast cancer. There were 150 highly relevant intersecting targets between seaweed-kunbu and breast cancer, and 10 core genes including Serine/threonine kinase 1 (AKT1), p53 tumor protein (TP53), tumor necrosis factor (TNF), interleukin6 (IL6), vascular endothelial growth factor A (VEGFA), JUN, caspase 3 (CASP3), interleukin1B (IL1B), MYC and human epidermal growth factor receptor (EGFR) were screened out. GO analysis indicated that these compounds may be involved in biological processes such as signal transduction, apoptosis, cell proliferation, and inflammatory response. KEGG pathway analysis showed that the main enriched signaling pathways were PI3K/Akt, MAPK and TNF. Molecular docking and in vitro experimental results demonstrated that fucosterol, the main chemical component of seaweed-kunbu, had an antiproliferative effect on triple-negative breast cancer BT-549 cells.
Seaweed-kunbu may treat breast cancer through multiple targets and pathways, and its main chemical component fucosterol can effectively inhibit the proliferation activity of BT-549 cells.
| [1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
|
| [2] |
BARZAMAN K, KARAMI J, ZAREI Z, et al. Breast cancer: biology, biomarkers, and treatments[J]. Int Immunopharmacol, 2020, 84: 106535.
|
| [3] |
韦明婵, 林江, 易劲苍, 等. 含海洋中药的抗肿瘤方剂用药规律分析[J]. 北京中医药大学学报, 2018, 41(3): 253-258. doi: 10.3969/j.issn.1006-2157.2018.03.013
|
| [4] |
HSIAO H H, WU T C, TSAI Y H, et al. Effect of oversulfation on the composition, structure, and in vitro anti-lung cancer activity of fucoidans extracted from Sargassum aquifolium[J]. Mar Drugs, 2021, 19(4): 215.
|
| [5] |
TSOU M H, LEE C C, WU Z Y, et al. Bioactivity of crude fucoidan extracted from Sargassum ilicifolium (Turner) C. Agardh[J]. Sci Rep, 2022, 12(1): 15916.
|
| [6] |
PRADHAN B, PATRA S, NAYAK R, et al. Multifunctional role of fucoidan, sulfated polysaccharides in human health and disease: a journey under the sea in pursuit of potent therapeutic agents[J]. Int J Biol Macromol, 2020, 164: 4263-4278.
|
| [7] |
WANG X, WANG Z Y, ZHENG J H, et al. TCM network pharmacology: a new trend towards combining computational, experimental and clinical approaches[J]. Chin J Nat Med, 2021, 19(1): 1-11.
|
| [8] |
NAMVAR F, MOHAMAD R, BAHARARA J, et al. Antioxidant, antiproliferative, and antiangiogenesis effects of polyphenol-rich seaweed (Sargassum muticum)[J]. Biomed Res Int, 2013, 2013: 604787.
|
| [9] |
SHARMA A, KASHYAP D, SAK K, et al. Therapeutic charm of quercetin and its derivatives: a review of research and patents[J]. Pharm Pat Anal, 2018, 7(1): 15-32.
|
| [10] |
YARLA N S, BISHAYEE A, SETHI G, et al. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy[J]. Semin Cancer Biol, 2016, 40/41: 48-81.
|
| [11] |
MONTEIRO P, LOMARTIRE S, COTAS J, et al. Call the eckols: present and future potential cancer therapies[J]. Mar Drugs, 2022, 20(6): 387.
|
| [12] |
LI X, ZHOU D Y, LI F T, et al. Saringosterol acetate isolated from Sargassum fusiformis induces mitochondrial-mediated apoptosis in MCF-7 breast cancer cells[J]. Chem Biodivers, 2022, 19(3): e202100848.
|
| [13] |
杨玲, 郑超群, 吴福珍, 等. 岩藻甾醇对卵巢癌细胞抑制作用的体外研究[J]. 北方药学, 2020, 17(5): 145-146, 196.
|
| [14] |
MAO Z F, SHEN X L, DONG P, et al. Fucosterol exerts antiproliferative effects on human lung cancer cells by inducing apoptosis, cell cycle arrest and targeting of Raf/MEK/ERK signalling pathway[J]. Phytomedicine, 2019, 61: 152809.
|
| [15] |
XU H, LIN F J, WANG Z L, et al. CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2[J]. Cancer Lett, 2018, 412: 69-80.
|
| [16] |
LI C W, XIA W Y, LIM S O, et al. AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent Twist1 degradation[J]. Cancer Res, 2016, 76(6): 1451-1462.
|
| [17] |
JEOUNG D I, TANG B, SONENBERG M. Effects of tumor necrosis factor-alpha on antimitogenicity and cell cycle-related proteins in MCF-7 cells[J]. J Biol Chem, 1995, 270(31): 18367-18373.
|
| [18] |
SLATTERY M L, HERRICK J S, TORRES-MEJIA G, et al. Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study[J]. Carcinogenesis, 2014, 35(8): 1750-1759.
|
| [19] |
JOHNSON D E, O'KEEFE R A, GRANDIS J R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer[J]. Nat Rev Clin Oncol, 2018, 15(4): 234-248.
|
| [20] |
KAJAL K, BOSE S, PANDA A K, et al. Transcriptional regulation of VEGFA expression in T-regulatory cells from breast cancer patients[J]. Cancer Immunol Immunother, 2021, 70(7): 1877-1891.
|
| [21] |
QIAO Y C, HE H, JONSSON P, et al. AP-1 is a key regulator of proinflammatory cytokine TNFα-mediated triple-negative breast cancer progression[J]. J Biol Chem, 2016, 291(35): 18309.
|
| [22] |
PU X, STORR S J, ZHANG Y M, et al. Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival[J]. Apoptosis, 2017, 22(3): 357-368.
|
| [23] |
LIU Y Q, ZHU C J, TANG L, et al. MYC dysfunction modulates stemness and tumorigenesis in breast cancer[J]. Int J Biol Sci, 2021, 17(1): 178-187.
|
| [24] |
ZHAO L N, QIU T, JIANG D W, et al. SGCE promotes breast cancer stem cells by stabilizing EGFR[J]. Adv Sci, 2020, 7(14): 1903700.
|
| [25] |
LI K, ZHANG T T, ZHAO C X, et al. Faciogenital Dysplasia 5 supports cancer stem cell traits in basal-like breast cancer by enhancing EGFR stability[J]. Sci Transl Med, 2021, 13(586): eabb2914.
|
| [26] |
SONG X, LIU Z Y, YU Z Y. EGFR promotes the development of triple negative breast cancer through JAK/STAT3 signaling[J]. Cancer Manag Res, 2020, 12: 703-717.
|
| [27] |
ZHAO Y Y, MA J, FAN Y L, et al. TGF-β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways[J]. Mol Oncol, 2018, 12(3): 305-321.
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: